Article Sidebar
Published:
Feb 18, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of etanercept in rheumatoid arthritis patients and its effects on interleukin 6 and serum tumor necrosis factor α
Abstract
Purpose: To study the effects of etanercept (ETA) on the clinical manifestations and serum levels of TNF-α and IL-6 in rheumatoid arthritis (RA) patients.
Methods: A retrospective analysis was performed on the medical files of 138 active RA patients admitted to Guangdong Second Provincial General Hospital, Guangzhou, China for rheumatic diseases from January 2016 to February 2019. Out of the total subjects, 58 patients were administered conventional methotrexate (MTX) as routine treatment (control group), while the remaining 80 patients (classified as study group) received subcutaneous injection of etanercept (ETA). Health Assessment Questionnaire (HAQ) score, and TNF-α and IL-6 serum concentrations of the two groups before and after treatment were assessed.
Results: Pre-treatment HAQ score was comparable in both groups (p > 0.05). However, at 3, 6, 9 and 12 weeks post-treatment, HAQ scores decreased in the two groups. The mean score was significantly lower in study group than in control group (p < 0.001). Pre-treatment serum levels of IL-6 and TNF-α in both groups were comparable. However, after treating for 3, 6, 9 and 12 weeks, serum IL-6 and TNF-α decreased significantly, with lower values in the study group than in control group (p < 0.001).
Conclusion: ETA has a higher efficacy and safety than MTX for the treatment of joint inflammation and and also achieved greater improvement of joint function. However, further clinical trials are recommended prior to wider application in clinical practice.
